MedTrace Logo

A Study to Assess the Effect of Single Doses of Daridorexant on Electrocardiogram Parameters in Healthy Subjects

NCT04250506 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2020-09-16

No results posted yet for this study

Summary

A study to assess the effect of single doses of daridorexant on electrocardiogram parameters in healthy subjects

Conditions

  • Healthy

Interventions

DRUG

Daridorexant

Daridorexant (ACT-541468) administered as film-coated tablets for oral use.

DRUG

Placebo

Placebo administered as tablets for oral use.

DRUG

Moxifloxacin

Moxifloxacin administered as film-coated tablets for oral use.

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idorsia Pharmaceuticals Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-28
Primary Completion
2020-07-22
Completion
2020-07-22

Countries

  • Czechia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04250506 on ClinicalTrials.gov